MARKSANS — Marksans Pharma Share Price
0.000.00%
Last trade - 00:00- IN₹119.20bn
- IN₹115.56bn
- IN₹26.23bn
- 64
- 11
- 61
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 23.2 | ||
| PEG Ratio (f) | 1.12 | ||
| EPS Growth (f) | 26.26% | ||
| Dividend Yield (f) | 1.09% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.83 | ||
| Price to Tang. Book | 5.07 | ||
| Price to Free Cashflow | 353.25 | ||
| Price to Sales | 4.54 | ||
| EV to EBITDA | 21.86 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.12% | ||
| Return on Equity | 16.8% | ||
| Operating Margin | 16.98% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 13,761.82 | 14,908.39 | 18,521.39 | 21,774.07 | 26,228.45 | 31,644 | 36,481 | 18.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +98.11 | -23.32 | +42.28 | +12.09 | +16.8 | +26.19 | +26.42 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Marksans Pharma Limited is an India-based company, which is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two research and development centers, one located in Goa and the other in Navi Mumbai. The Company's product portfolio spreads various therapeutic segments of the cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products (over-the-counter) include pain management, upper respiratory, digestive health, vitamins, minerals and supplements (VMS) and skin care products. Its prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic.
Directors
- Mark Saldanha CHM
- Harshavardhan Panigrahi CCO
- Varddhman Jain EDR
- Sandra Saldanha EDR (42)
- Sunny Sharma NED
- Digant Parikh IND
- Meena Surana IND
- Seetharama Buddharaju NID
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- April 16th, 1992
- Public Since
- April 3rd, 2002
- No. of Employees
- 2,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 453,163,746
- Address
- 21 Lotus Business Park, MUMBAI, 400053
- Web
- https://www.marksanspharma.com/
- Phone
- +91 2240012000
- Contact
- Harshavardhan Panigrahi
- Auditors
- MSKA & Associates
Upcoming Events for MARKSANS
Marksans Pharma Ltd Annual Shareholders Meeting
Q2 2026 Marksans Pharma Ltd Earnings Release
Similar to MARKSANS
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Marksans Pharma share price?
As of Today at 21:53 UTC, shares in Marksans Pharma are trading at IN₹263.05. This share price information is delayed by 15 minutes.
How has the Marksans Pharma share price performed this year?
Shares in Marksans Pharma last closed at IN₹263.05 and the price had moved by +58.43% over the past 365 days. In terms of relative price strength the Marksans Pharma share price has outperformed the S&P BSE 100 Index by +52.78% over the past year.
What are the analyst and broker recommendations for Marksans Pharma?
The overall consensus recommendation for Marksans Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Marksans Pharma dividend yield?
The Marksans Pharma dividend yield is 0.3% based on the trailing twelve month period.
Does Marksans Pharma pay a dividend?
Last year, Marksans Pharma paid a total dividend of IN₹0.80, and it currently has a trailing dividend yield of 0.3%. We do not have any data on when Marksans Pharma is to next pay dividends.
When does Marksans Pharma next pay dividends?
We do not have data on when Marksans Pharma is to next pay dividends. The historic dividend yield on Marksans Pharma shares is currently 0.3%.
How do I buy Marksans Pharma shares?
To buy shares in Marksans Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Marksans Pharma?
As of the previous close price of IN₹263.05, shares in Marksans Pharma had a market capitalisation of IN₹119.20bn.
Where are Marksans Pharma shares listed?
Here are the trading details for Marksans Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: MARKSANS
What kind of share is Marksans Pharma?
Based on an overall assessment of its quality, value and momentum Marksans Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Marksans Pharma share price forecast for 2025?
The analyst consensus target price for shares in Marksans Pharma is IN₹294.00. That is 11.77% above the last closing price of IN₹263.05.
Analysts covering Marksans Pharma currently have a consensus Earnings Per Share (EPS) forecast of IN₹10.60 for the next financial year.
Find out moreWhat is the trend in the Marksans Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Marksans Pharma. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -17.36%.
As of the last closing price of IN₹263.05, shares in Marksans Pharma were trading +0.45% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Marksans Pharma PE Ratio?
The Marksans Pharma PE ratio based on its reported earnings over the past 12 months is 23.2. The shares last closed at IN₹263.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Marksans Pharma?
Marksans Pharma's management team is headed by:
- Mark Saldanha - CHM
- Harshavardhan Panigrahi - CCO
- Varddhman Jain - EDR
- Sandra Saldanha - EDR
- Sunny Sharma - NED
- Digant Parikh - IND
- Meena Surana - IND
- Seetharama Buddharaju - NID